Literature DB >> 10674029

Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation.

E Bailey1, M J Bottomley, S Westwell, J H Pringle, P N Furness, J Feehally, P E Brenchley, S J Harper.   

Abstract

AIM: To investigate vascular endothelial growth factor (VEGF) mRNA expression in glomerular disease in the context of heavy proteinuria.
METHODS: Non-radioisotopic in situ hybridisation was performed using a cocktail of 12 deoxyoligonucleotides complementary to VEGF mRNA labelled during solid phase synthesis with 2,4-dinitrophenyl. Archival renal biopsies were studied from cases of minimal change nephropathy, membranous nephropathy, diabetic nephropathy, and controls, matched for age, sex, race, and storage time. Hybrid detection used NBT/BCIP colorimetric development.
RESULTS: More VEGF mRNA positive glomerular cells per unit cross sectional diameter were seen in minimal change nephropathy (mean (SEM), 19.35 (1.5)) compared with controls (12.6 (1.73)), p < 0.01. In contrast, fewer were seen in diabetic nephropathy (5.93 (0.97)) compared with controls (9.97 (1.25)), p < 0.03. Analysis of membranous nephropathy (10 (1.62)) showed no difference from controls (10.98 (1.51)), NS. In addition, in minimal change nephropathy there was a significant correlation between 24 hour protein excretion at the time of biopsy and the number of VEGF mRNA cells per glomerulus (r = 0.08, p = 0.01).
CONCLUSIONS: Using non-radioisotopic in situ hybridisation, VEGF mRNA is almost exclusively expressed by visceral glomerular epithelial cells. Abnormal numbers of cells are seen in both minimal change and diabetic nephropathy. As VEGF exists in a number of functionally distinct isoforms, further study of qualitative VEGF isoform expression in diagnostic groups is indicated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10674029      PMCID: PMC501565          DOI: 10.1136/jcp.52.10.735

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

Review 1.  The biology of vascular endothelial growth factor.

Authors:  N Ferrara; T Davis-Smyth
Journal:  Endocr Rev       Date:  1997-02       Impact factor: 19.871

2.  A comparative study of digoxigenin, 2,4-dinitrophenyl, and alkaline phosphatase as deoxyoligonucleotide labels in non-radioisotopic in situ hybridisation.

Authors:  S J Harper; E Bailey; C M McKeen; A S Stewart; J H Pringle; J Feehally; T Brown
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 3.  Proteinuria--a direct cause of renal morbidity?

Authors:  J D Williams; G A Coles
Journal:  Kidney Int       Date:  1994-02       Impact factor: 10.612

4.  VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix.

Authors:  Z Poltorak; T Cohen; R Sivan; Y Kandelis; G Spira; I Vlodavsky; E Keshet; G Neufeld
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

5.  Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

Authors:  D R Senger; D T Connolly; L Van de Water; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

6.  Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites.

Authors:  M Simon; W Röckl; C Hornig; E F Gröne; H Theis; H A Weich; E Fuchs; A Yayon; H J Gröne
Journal:  J Am Soc Nephrol       Date:  1998-06       Impact factor: 10.121

7.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

8.  Vascular permeability factor mRNA and protein expression in human kidney.

Authors:  L F Brown; B Berse; K Tognazzi; E J Manseau; L Van de Water; D R Senger; H F Dvorak; S Rosen
Journal:  Kidney Int       Date:  1992-12       Impact factor: 10.612

9.  Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases.

Authors:  K Shulman; S Rosen; K Tognazzi; E J Manseau; L F Brown
Journal:  J Am Soc Nephrol       Date:  1996-05       Impact factor: 10.121

10.  Angiogenesis and vascular endothelial growth factor (VEGF): is it relevant in renal patients?

Authors:  H J Gröne
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

View more
  24 in total

1.  Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.

Authors:  D Veron; C A Bertuccio; A Marlier; K Reidy; A M Garcia; J Jimenez; H Velazquez; M Kashgarian; G W Moeckel; A Tufro
Journal:  Diabetologia       Date:  2011-02-12       Impact factor: 10.122

2.  Effect of tumor necrosis factor alpha and vascular permeability growth factor on albuminuria in rats.

Authors:  Paul F Laflam; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2005-10-07       Impact factor: 3.714

3.  Urinary Markers of Podocyte Dysfunction in Chronic Glomerulonephritis.

Authors:  Natalia Chebotareva; Irina Bobkova; Lidia Lysenko; Sergey Moiseev
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli.

Authors:  Andrew H J Salmon; Christopher R Neal; David O Bates; Steven J Harper
Journal:  J Physiol       Date:  2005-10-20       Impact factor: 5.182

5.  The study on the relationship between serum vascular endothelial growth factor and proteinuria in adriamycin-induced nephrotic rats.

Authors:  Z Zhu; Y Wang; H Wang; A Deng
Journal:  J Tongji Med Univ       Date:  2001

Review 6.  Vascular endothelial growth factor and diabetic nephropathy.

Authors:  Sheldon Chen; Fuad N Ziyadeh
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

7.  Abnormal angiogenesis in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Tomoki Kosugi; Masakazu Haneda; Christopher J Rivard; David A Long
Journal:  Diabetes       Date:  2009-07       Impact factor: 9.461

8.  Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes.

Authors:  Cathy Grutzmacher; SunYoung Park; Yun Zhao; Margaret E Morrison; Nader Sheibani; Christine M Sorenson
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-17

Review 9.  The podocyte as a direct target for treatment of glomerular disease?

Authors:  Sandeep K Mallipattu; John C He
Journal:  Am J Physiol Renal Physiol       Date:  2016-04-20

10.  GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin.

Authors:  Honghui Wang; Taro Misaki; Vanessa Taupin; Akiko Eguchi; Pradipta Ghosh; Marilyn G Farquhar
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.